Delivery Order SPE2DB25D3108-SPE2DB25FPDPA
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $5,762.72 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pen injectors on August 5, 2025, with completion scheduled for August 6, 2025. This firm fixed-price delivery order represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract falls under the company's existing...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,525.20 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 25, 2025, with completion scheduled for July 28, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $19,637.21 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 ml pens on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $5,431.13 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 23, 2025, with an ultimate completion date of July 24, 2025. The contract represents a firm fixed price delivery order with no set-aside designation, competitively awarded to support federal medical procurement needs. Performance will be executed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections, with a ceiling value of $7,724.28. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a non-competitive, non-set-aside award. The product will be delivered to AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This award is issued as a child...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections valued at $10,445.54 on August 7, 2025, with completion scheduled for August 8, 2025. This firm fixed-price delivery order was competitively awarded without set-aside provisions and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.999 billion prime vendor agreement...
- The Defense Logistics Agency awarded a $2,697.75 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Zepbound (semaglutide) 2.5 mg/0.5 mL pen injections. The contract is a firm fixed-price delivery order with no set-aside designation, reflecting AmerisourceBergen's ability to compete successfully in open federal procurement. Performance will be completed by July 21, 2025, with fulfillment occurring at the contractor's facility in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections, with a ceiling value of $2,287.74. The award, issued on July 24, 2025, represents a firm fixed price delivery order with a completion date of July 25, 2025, indicating a short-duration, expedited fulfillment requirement. This contract was competitively awarded without set-aside designations, executed under AmerisourceBergen's broader...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,205.08 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pen injections on August 1, 2025, with an ultimate completion date of August 4, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The delivery...
- The Defense Logistics Agency awarded a $21,483.49 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injectors on July 28, 2025, with an ultimate completion date of July 29, 2025. The contract was competitively awarded without set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- SPE2DB25D3108Indefinite Delivery Contract
- SPE2DB25D3108-SPE2DB25FPDPADelivery Order
The Defense Logistics Agency awarded a delivery order valued at $6,223.96 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 12.5 mg/0.5 mL pen injections on August 7, 2025, with completion scheduled for August 8, 2025. This competitively awarded, firm fixed-price delivery order was issued without a set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999.99 billion comprehensive pharmaceutical supply vehicle running through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Health Agency and related government healthcare entities. The company's extensive federal contract portfolio demonstrates its capability to supply diverse pharmaceutical products, medical devices, and specialized healthcare commodities across multiple therapeutic domains. This delivery order for Zepbound, a diabetes medication, exemplifies the company's role in fulfilling ongoing medical supply requirements through the DLA's flexible contract vehicle designed to support global military healthcare programs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $6.2k | 8/7/25 |